The estimated Net Worth of Jon T Holmlund is at least $408 Thousand dollars as of 1 September 2021. Jon Holmlund owns over 47,756 units of Galera Therapeutics Inc stock worth over $3,486 and over the last 5 years he sold GRTX stock worth over $0. In addition, he makes $404,460 as Chief Medical Officer at Galera Therapeutics Inc.
Sign up
Jon Holmlund GRTX stock SEC Form 4 insiders trading
Jon has made over 7 trades of the Galera Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 47,756 units of GRTX stock worth $116,047 on 1 September 2021.
The largest trade he's ever made was exercising 47,756 units of Galera Therapeutics Inc stock on 1 September 2021 worth over $116,047. On average, Jon trades about 7,604 units every 48 days since 2020. As of 1 September 2021 he still owns at least 47,756 units of Galera Therapeutics Inc stock.
You can see the complete history of Jon Holmlund stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jon Holmlund biography
Dr. Jon T. Holmlund M.D. serves as Chief Medical Officer of the Company. Dr. Holmlund previously served as the Chief Medical Officer of Ascenta Therapeutics from April 2004 until November 2007 and at Isis (now lonis) Pharmaceuticals from August 1997 until March 2004, including as Vice President of Development from March 2003 until March 2004. Dr. Holmlund has also been an independent consultant on oncology drug development to the biopharmaceutical industry. He previously served as Medical Director of Aspire IRB, LLC, and as a senior investigator in the National Cancer lnstitute’s Cancer Therapy Evaluation Program and Biological Response Modifiers Programs. Dr. Holmlund received his M.D. from SUNY Buffalo and completed postgraduate training in internal medicine and medical oncology at George Washington University Medical Center.
What is the salary of Jon Holmlund?
As the Chief Medical Officer of Galera Therapeutics Inc, the total compensation of Jon Holmlund at Galera Therapeutics Inc is $404,460. There are 7 executives at Galera Therapeutics Inc getting paid more, with J. Mel Sorensen having the highest compensation of $2,465,100.
How old is Jon Holmlund?
Jon Holmlund is 63, he's been the Chief Medical Officer of Galera Therapeutics Inc since 2012. There are 6 older and 9 younger executives at Galera Therapeutics Inc. The oldest executive at Galera Therapeutics Inc is Joel F. Sussman, 72, who is the Chief Accounting Officer & Treasurer.
What's Jon Holmlund's mailing address?
Jon's mailing address filed with the SEC is C/O GALERA THERAPEUTICS, INC.,, 2 W LIBERTY BLVD #100, MALVERN, PA, 19355.
Insiders trading at Galera Therapeutics Inc
Over the last 5 years, insiders at Galera Therapeutics Inc have traded over $19,201,067 worth of Galera Therapeutics Inc stock and bought 3,540,438 units worth $29,883,202 . The most active insiders traders include Holdings A/S Novo, Group Inc Blackstone Group ..., and Bioventures Ltd Novartis Ag.... On average, Galera Therapeutics Inc executives and independent directors trade stock every 47 days with the average trade being worth of $11,809. The most recent stock trade was executed by Mel Sorensen on 16 August 2024, trading 67,015 units of GRTX stock currently worth $4,691.
What does Galera Therapeutics Inc do?
galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.
What does Galera Therapeutics Inc's logo look like?
Complete history of Jon Holmlund stock trades at Galera Therapeutics Inc
Galera Therapeutics Inc executives and stock owners
Galera Therapeutics Inc executives and other stock owners filed with the SEC include:
-
J. Mel Sorensen,
President, Chief Executive Officer, Director -
Christopher Degnan,
Chief Financial Officer -
Robert Beardsley,
Chief Operating Officer -
Dr. J. Mel Sorensen,
CEO, Pres & Director -
Christopher Degnan,
CFO & Sec. -
Dr. Robert A. Beardsley,
Co-Founder & COO -
Arthur Fratamico,
Chief Business Officer -
Jon Holmlund,
Chief Medical Officer -
Lawrence Alleva,
Independent Director -
Michael Powell,
Independent Chairman of the Board -
Emmett Cunningham,
Director -
Kevin Lokay,
Independent Director -
Linda West,
Independent Director -
Joel Sussman,
Chief Accounting Officer -
Mark J. Bachleda M.B.A., Pharm.D.,
Chief Commercial Officer -
Arthur J. Fratamico,
Chief Bus. Officer -
Dr. Jon T. Holmlund,
Chief Medical Officer -
Jennifer Evans Stacey Esq.,
Chief Legal & Compliance Officer and Sec. -
Dr. Dennis P. Riley Ph.D.,
Chief Scientific Officer -
Joel F. Sussman,
Chief Accounting Officer & Treasurer -
Bioventures Ltd Novartis Ag...,
-
Chris Degnan,
Chief Financial Officer -
Jason Fuller,
Director -
Iv A, L.P.Clarus Iv B, L.P....,
-
Group Inc Blackstone Group ...,
-
Clarus Gp L.P.Blackstone Cl...,
-
Enterprise Associates 14, L...,
-
Venture Partners Ix, L.P.So...,
-
Dennis Riley,
Chief Scientific Officer -
Holdings A/S Novo,
10% owner -
Mark Bachleda,
Chief Commercial Officer -
Jennifer Evans Stacey,
See Remarks -
Yair Schneid,
10% owner -
Eugene P. Kennedy,
Chief Medical Officer -
Mel Sorensen,
President and CEO